Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Patent
1999-03-01
2000-08-29
Dentz, Bernard
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
546119, 546120, A61K 31435, C07D47104
Patent
active
061109320
ABSTRACT:
This invention is directed to compounds of the formula ##STR1## and the pharmaceutically-acceptable salts thereof, where the substituents are as defined in the Specification, which are growth hormone secretogogues and which increase the level of endogenous growth hormone. The compounds of this invention are useful for the treatment and prevention of osteoporosis, congestive heart failure, frailty associated with aging, obesity; accelerating bone fracture repair, attenuating protein catabolic response after a major operation, reducing cachexia and protein loss due to chronic illness, accelerating would healing, or accelerating the recovery of burn patients or patients having undergone major surgery; improving muscle strength, mobility, maintanence of skin thickness, metabolic homeostasis or renal homeostasis. The compounds of the present invention are also useful in treating osteoporosis when used in combination with: a bisphosphonate compound such as alendronate; estrogen, premarin, and optionally progesterone; an estrogen agonist or antagonist; or calcitonin, and pharmaceutical compositions useful therefor. Further, the present invention is directed to pharmaceutical compositions useful for increasing the endogenous production or release of growth hormone in a human or other animal which comprises an effective amount of a compound of the present invention and a growth hormone secretagogue selected from GHRP-6, Hexarelin, GHRP-1, growth hormone releasing factor (GRF), IGF-1, IGF-2, or B-HT920. The invention is also directed to intermediates useful in the preparation of compounds of formula I.
REFERENCES:
Chemical Abstracts, vol. 86, Abstract No. 86:155590, 1977.
Tetrahedron, Morena-Manas, vol. 50, No. 2, 1994, pp. 515-528.
Eur. Journal of Endocrinology, Marie Degerhblad et al, 1995, 133:180-8
Eur. Journal of Endocrinology, Jens Of Jorgensen et al, 1994, 130:224-8.
Journal of Clinical Endocrinology and Metabolish, K. C. Copeland et al, 1994, vol. 78, pp. 1040-1047.
Journal of Clinical Endocrinilogy and Metabolism, Joseph A. Aloi et al, 1994, vol. 79, pp. 943-949.
The New England Journal of Medicine, Evan Loh et al, 1996, vol. 334, No. 13, pp. 856-857.
The New England Journal of Medicine, Serafino Fazio et al, vol. 334, No. 13, 1996, pp. 809-814.
Circulation, Antonio Cittadini et al, vol. 93, No. 4, Feb. 15, 1996, pp. 800-808.
Circulation, Renhui Yang et al, vol. 92, No. 2, Jul. 15, 1995, pp. 262-267.
Hormone Res. 1995, 43, pp. 93-99, Thord Rosen.
The Martindale The Extra Pharma Copia 30a. Ed. The Parm Press, Londres, 1993, pp. 655-657.
Carpino Philip A
DaSilva-Jardine Paul A
Lefker Bruce A
Ragan John A
Benson Gregg C.
Dentz Bernard
Pfizer Inc.
Richardson Peter C.
Ronau Robert T.
LandOfFree
Growth hormone secretagogues does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Growth hormone secretagogues, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Growth hormone secretagogues will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-1250205